Show simple item record

dc.contributorReal World Data Working Group
dc.contributor.authorVivanco-Hidalgo, Rosa Maria
dc.contributor.authorMolina, Israel
dc.contributor.authorMartinez, Elisenda
dc.contributor.authorRoman-Viñas, Ramón
dc.contributor.authorSánchez-Montalvá, Adrián
dc.contributor.authorFibla Palazón, Joan
dc.contributor.authorPontes, Caridad
dc.contributor.authorVelasco Muñoz, César
dc.date.accessioned2021-04-07T10:06:52Z
dc.date.available2021-04-07T10:06:52Z
dc.date.issued2021
dc.identifier.issn1560-7917
dc.identifier.issn1025-496X
dc.identifier.urihttp://hdl.handle.net/10459.1/70934
dc.description.abstractBackground: Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). Aim: To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine. Methods: We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes. Results: We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1.4%) COVID-19 cases in the exposed cohort and 183 (1.4%) among controls. The incidence rate was very similar between the two groups (12.05 vs 11.35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1.08; 95% confidence interval (CI): 0.83–1.44; p=0.50). Forty cases (0.6%) were admitted to hospital in the exposed cohort and 50 (0.4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0.91–2.34; p=0.10). Conclusions: Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population.ca_ES
dc.language.isoengca_ES
dc.publisherEuropean Centre for Disease Prevention and Controlca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.2807/1560-7917.ES.2021.26.9.2001202ca_ES
dc.relation.ispartofEurosurveillance, 2021, vol. 26, num. 9, p. 2001202ca_ES
dc.rightscc-by (c) Vivanco-Hidalgo et al., 2021ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.otherCOVID-19 (Malaltia)ca_ES
dc.titleIncidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020ca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.identifier.idgrec031264
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.2807/1560-7917.ES.2021.26.9.2001202


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c) Vivanco-Hidalgo et al., 2021
Except where otherwise noted, this item's license is described as cc-by (c) Vivanco-Hidalgo et al., 2021